UNITED STATES SECURITIES AND EXCHANGE COMMISSION Form 144 Filer Information Washington, D.C. 20549

Form 144

FORM 144

NOTICE OF PROPOSED SALE OF SECURITIES

PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

144: Filer Information

Filer CIK 0001779990 Filer CCC XXXXXXXX Is this a LIVE or TEST Filing? LIVE TEST

Submission Contact Information

Name Phone

E-Mail Address

144: Issuer Information

Name of Issuer Apogee Therapeutics, Inc.

SEC File Number 001-41740

221 CRESCENT ST.

BUILDING 17, SUITE 102B

Address of Issuer **WALTHAM**

MASSACHUSETTS

02453

Phone 650-394-5230

Name of Person for Whose Account the Securities are To Be Sold HENDERSON MICHAEL THOMAS

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer Officer Relationship to Issuer Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value		Approximate Date of Sale	Name the Securities Exchange
COMMON	RBC CAPITAL MARKETS LLC 250 NICOLLET MALL, SUITE 1700 MINNEAPOLIS MN 55401	15000	698709.00	58546027	12/04/2024	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
COMMON	05/02/2022 I	INCENTIVE UNIT CONVERSION	ISSUER			15000	05/02/2022 N/	A

^{*} If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
MICHAEL HENDERSON C/O RBC CAPITAL MARKETS LLC 250 NICOLLET MALL MINNEAPOLIS MN 55401	APOGEE THERAPEUTICS INC	10/02/2024	40000	2249176.00
MICHAEL HENDERSON C/O RBC CAPITAL MARKETS LLC 250 NICOLLET MALL MINNEAPOLIS MN 55401	APOGEE THERAPEUTICS INC	11/06/2024	15000	888388.00

144: Remarks and Signature

Remarks SOLD PURSUANT TO A RULE 10B5-1 PLAN

ESTABLISHED 09/25/2023

Date of Notice 12/04/2024

Date of Plan Adoption or Giving of Instruction, If Relying on 09/25/2023

Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature POA / JEFFREY EISCHENS

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)